查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
胃癌治療市場規模、份額和趨勢分析報告：按治療類型、疾病適應症、給藥途徑、藥物類別、分銷渠道、地區、細分市場預測，2022-2030 年
市場調查報告書
商品編碼
1122228

胃癌治療市場規模、份額和趨勢分析報告：按治療類型、疾病適應症、給藥途徑、藥物類別、分銷渠道、地區、細分市場預測，2022-2030 年

Stomach Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Disease Indication, By Route Of Administration, By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 140 Pages | 商品交期: 2-10個工作天內

價格

胃癌治療市場增長和趨勢

根據 Grand View Research, Inc. 的一份新報告，到 2030 年，全球胃癌治療市場規模預計將達到 112 億美元，從 2022 年到 2030 年，複合年增長率為 12.9%。免疫療法和靶向療法的增加以及新藥的推出預計將推動增長。

根據Globocan的數據，2020年胃癌的發病率約為110萬，預計到2030年將增加到142萬。對該疾病分子基礎知識的進步導致了靶向和免疫治療劑的開發和商業化。自 2010 年以來，赫賽汀等 HER-2 靶向藥物已上市。此外，一種名為 Cyramza 的靶向藥物是一種 VEGF 靶向單克隆抗體，自 2014 年以來已上市。目前，EGFR和PD-1靶向藥物和免疫療法正在開發作為胃癌的治療藥物。

臨床管道中藥物的批准和隨後的上市也有望推動胃癌治療市場。例如，2021年3月，國家藥監局批准Eli Lilly和Innovent Biologics的PD-1抑製劑藥物Sintilimab在中國用於治療胃或胃食管結合部腺癌。此外，2020 年 5 月，美國 FDA 授予 Enhertu 用於胃癌的孤兒藥資格。然後，在 2021 年 1 月，美國 FDA 批准 Enhertu 用於治療晚期或轉移性疾病。

赫賽汀等主要藥物的專利到期以及隨後推出的生物類似藥預計將抑制胃癌治療市場的增長。此外，由於成本高昂而導致靶向治療的低採用率也可能阻礙市場增長。例如，與其他藥物相比，Cyramza 被認為成本效益較低。由於成本效益低，在英國被 NICE 拒絕。此外，與臨床相關的比較者相比，法國拒絕報銷，因為缺乏額外的好處。

胃癌治療市場報告亮點

由於強大的臨床管道和新產品的批准，靶向治療治療類型在 2021 年佔銷售額的第二大份額。例如，2021年1月，美國FDA批准Enhertu用於治療轉移性或局部晚期HER-2陽性胃癌患者。

按治療類型，由於 Opdivo 和 Keytruda 等 PD-1 抑製劑在胃癌治療市場的引入和採用，預計免疫治療在預測期內增長最快。

根據指示，胃癌/胃食管結合部癌由於其高患病率和產品種類繁多，預計在預測期內將保持領先地位。由於產品推出數量的增加，胃腸道間質瘤（GIST）部分預計將增長

從分銷渠道來看，2021年胃癌治療市場由專業藥房和零售藥房主導。靶向和免疫治療藥物通常在儲存和物流方面有特殊要求，並且通常通過專業藥房分發。

由於該地區的高疾病負擔和研究計劃，預計亞太地區將在預測期內保持其主導地位。根據 Globocan 的報告，到 2020 年，亞洲將佔新增胃癌病例的約 75.3%。

由於患者人數增加以及靶向和免疫治療藥物的批准，預計歐洲在預測期內將出現顯著增長。

目錄

第一章 調查方法和範圍

  • 調查方法
  • 調查假設
    • 估計/預測時間表
  • 調查方法
  • 信息採購
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要信息
    • 初步調查
    • 第一次調查的內容
  • 信息或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 型號詳情
    • 商品流向分析
      • 方法一：商品流動方法
      • 方法 2：使用自下而上的方法進行國別市場估算
  • 全球市場：複合年增長率計算
  • 二級信息列表
  • 主要信息列表
  • 目的
  • 表列表

第二章執行摘要

  • 市場概況
  • 市場細分

第三章市場變量、趨勢和範圍

  • 繪製滲透率和增長前景
  • 監管框架
  • 胃癌治療市場動態
    • 市場驅動力分析
      • 強大的產品管道
      • 疾病流行率增加
    • 市場約束分析
      • 目前批准的靶向治療缺乏報銷
    • 市場機會分析
  • PESTEL 分析
  • 波特五力分析
  • 重大交易和戰略聯盟分析
    • 新產品發布
    • 擴張
    • 合夥
    • 協議
  • 管道分析
    • 即將推出的主要產品分析
  • 各國流行病學分析
  • 未滿足的需求

第 4 章治療業務分析（患者佔比 %）

  • 胃癌治療市場：治療類型的變化分析
  • 化學處理
  • 免疫療法
  • 靶向治療
  • 放射治療和手術

第五章 適應症業務分析

  • 胃癌治療市場：疾病適應症的波動分析
  • 胃癌/食管胃結合部癌
  • 胃腸道間質瘤

6. 醫藥類業務分析（患者份額%）

  • 胃癌治療市場：藥物類別變化分析
  • PD-1/PD-L1 抑製劑
  • HER2拮抗劑
  • VEGFR2拮抗劑
  • 其他

第七章 管理渠道業務分析

  • 胃癌治療市場：給藥途徑的變化分析
  • 口服
  • 可注射的

第八章分銷渠道業務分析

  • 胃癌治療市場：分銷渠道波動分析
  • 醫院藥房
  • 專業和零售藥店
  • 其他

第九章區域估計與趨勢分析

  • 區域市場快照
    • 北美
      • 美國
      • 加拿大
    • 歐洲
      • 英國
      • 德國
      • 西班牙
      • 法國
      • 意大利
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 韓國
      • 澳大利亞
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 阿根廷
    • 中東和非洲
      • 南非
      • 沙特阿拉伯
      • 阿拉伯聯合酋長國

第 10 章胃癌市場 - 競爭分析

  • 主要市場參與者的最新發展和影響分析
  • 公司/競爭對手分類（主要創新者、市場領導者、初創企業）
  • 上市公司
    • 公司市場分析（收入、地域分佈、產品組合、關鍵服務行業、關鍵聯盟）
    • 競爭儀錶盤分析
      • 市場差異化因素
  • 民營企業
    • 主要初創企業/技術顛覆者/創新者名單
    • 區域網絡圖
    • 公司市場分析（地理分佈、產品組合、關鍵合作夥伴、行業經驗）
  • 公司簡介
    • Eli Lilly and Company
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • F. Hoffmann-La Roche Ltd.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Pfizer Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Novartis AG
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Merck & Co., Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Samsung Bioepis
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Biocon
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Mylan NV
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Teva Pharmaceutical Industries Ltd.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Celltrion Healthcare Co., Ltd.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
Product Code: GVR-4-68039-973-9

Stomach Cancer Treatment Market Growth & Trends:

The global stomach cancer treatment market size is expected to reach USD 11.2 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 12.9% from 2022 to 2030. Increasing uptake of immunotherapy and targeted therapy, coupled with the launch of new drugs, is expected to fuel growth.

According to Globocan, the incidence of gastric cancer in 2020 was around 1.1 million, which is expected to increase to 1.42 million by 2030. Increasing knowledge regarding the molecular basis of the disease has led to a rise in the number of targeted drugs and immunotherapy drugs being developed and launched in the market. HER-2 targeted drugs such as Herceptin have been available in the market since 2010. Another targeted drug, Cyramza, which is a VEGF-targeting monoclonal antibody, has been available since 2014. EGFR and PD-1 targeted drugs and immunotherapies are currently being developed for the treatment of gastric cancer.

The approval and subsequent launch of drugs in the clinical pipeline are also expected to drive the gastric cancer therapy market. For instance, in March 2021, the NMPA approved Eli Lilly and Innovent Biologics' drug Sintilimab, a PD-1 inhibitor, for the treatment of gastric or gastroesophageal junction adenocarcinoma in China. Furthermore, in May 2020, the U.S. FDA granted the orphan drug designation to Enhertu for the treatment of gastric cancers. Subsequently, in January 2021, the U.S. FDA approved Enhertu for the treatment of advanced or metastatic forms of the disease.

Patent expiry of key drugs such as Herceptin and subsequent launch of biosimilars are expected to restrain the growth of the gastric cancer therapy market. Additionally, lesser adoption of targeted therapy due to high costs might hamper the growth of the market. For instance, Cyramza was not considered cost-effective as compared to other drugs. It was rejected by NICE due to a lack of cost-effectiveness in England. Furthermore, the product was rejected for reimbursement in France due to a lack of additional benefits compared to the clinically relevant comparators.

Stomach Cancer Treatment Market Report Highlights:

  • The targeted therapy treatment type segment held the second-largest revenue share in 2021 due to the robust clinical pipeline and approval of new products. For instance, in January 2021, the U.S. FDA approved Enhertu for the treatment of patients with metastatic or locally advanced HER-2 positive gastric cancers
  • By treatment type, immunotherapy is anticipated to witness the fastest growth during the forecast period due to the launch and adoption of PD-1 inhibitors such as Opdivo and Keytruda in the gastric cancer therapy market
  • By disease indication, the gastric cancer/gastroesophageal junction cancer segment is expected to maintain its lead during the forecast period due to the high prevalence of the disease and the availability of various products. The gastrointestinal stromal tumors (GISTs) segment is expected to grow due to the increasing number of product launches
  • Based on the distribution channel, the specialty and retail pharmacies segment dominated the gastric cancer therapy market in 2021. Targeted and immunotherapy drugs often have special requirements in terms of storage and logistics and are therefore distributed by specialty pharmacies
  • Asia Pacific is expected to maintain its dominance during the forecast period due to the high disease burden and research initiatives in the region. According to a Globocan report, Asia accounts for around 75.3% of all new cases of gastric cancer in 2020
  • Europe is anticipated to witness considerable growth during the forecast period owing to the increasing target patient population and approval of targeted and immunotherapy drugs

TABLE of Contents

Chapter 1 Methodology and Scope

  • 1.1 Research Methodology
  • 1.2 Research Assumptions
    • 1.2.1 Estimates and Forecast Timeline
  • 1.3 Research Methodology
  • 1.4 Information Procurement
    • 1.4.1 Purchased Database
    • 1.4.2 GVR's Internal Database
    • 1.4.3 Secondary Sources
    • 1.4.4 Primary Research
    • 1.4.5 Details of Primary Research
  • 1.5 Information or Data Analysis
    • 1.5.1 Data Analysis Models
  • 1.6 Market Formulation & Validation
  • 1.7 Model Details
    • 1.7.1 Commodity Flow Analysis
      • 1.7.1.1 Approach 1: Commodity Flow Approach
      • 1.7.1.2 Approach 2: Country wise market estimation using bottom up approach
  • 1.8 Global Market: CAGR Calculation
  • 1.9 List of Secondary Sources
  • 1.10 List of Primary Sources
  • 1.11 Objectives
    • 1.11.1 Objective 1:
    • 1.11.2 Objective 2:
  • 1.12 List of TABLEs

Chapter 2 Executive Summary

  • 2.1 Market Summary
  • 2.2 Market Segmentation

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Penetration and Growth Prospect Mapping
  • 3.2 Regulatory framework
  • 3.3 Stomach Cancer Treatment Market Dynamics
    • 3.3.1 Market Driver Analysis
      • 3.3.1.1 Robust product pipeline
      • 3.3.1.2 Increasing prevalence of the disease
    • 3.3.2 Market Restraint Analysis
      • 3.3.2.1 Lack of reimbursement for currently approved targeted therapies
    • 3.3.3 Market Opportunity Analysis
  • 3.4 PESTEL Analysis
  • 3.5 Porter's Five Forces Analysis
  • 3.6 Major deals and strategic alliances analysis
    • 3.6.1 New product launch
    • 3.6.2 Expansion
    • 3.6.3 Partnership
    • 3.6.4 Agreements
  • 3.6 Pipeline Analysis
    • 3.6.1 Analysis of key upcoming products
  • 3.7 Epidemiology Analysis, by Country
  • 3.8 Unmet Needs

Chapter 4 Treatment Type Business Analysis (Patient Share in %)

  • 4.1 Stomach Cancer Treatment Market: Treatment Type Movement Analysis
  • 4.2 Chemotherapy
    • 4.2.1 Chemotherapy market estimates and forecast, 2018 - 2030
  • 4.3 Immunotherapy
    • 4.3.1 Immunotherapy market estimates and forecast, 2018 - 2030
  • 4.4 Targeted Therapy
    • 4.4.1 Targeted Therapy market estimates and forecast, 2018 - 2030
  • 4.4 Radiation therapy & Surgery

Chapter 5 Disease Indication Business Analysis

  • 5.1 Stomach Cancer Treatment Market: Disease Indication Movement Analysis
  • 5.2 Gastric Cancer/Gastroesophageal Junction Cancer
    • 5.2.1 Gastric Cancer/Gastroesophageal Junction Cancer market estimates and forecast, 2018 - 2030
  • 5.3 Gastrointestinal Stromal Tumors
    • 5.3.1 Gastrointestinal Stromal Tumors market estimates and forecast, 2018 - 2030

Chapter 6 Drug Class Business Analysis (Patient Share in %)

  • 6.1 Stomach Cancer Treatment Market: Drug Class Movement Analysis
  • 6.2 PD-1/PD-L1 inhibitors
    • 6.2.1 PD-1/PD-L1 inhibitors market estimates and forecast, 2018 - 2030
  • 6.3 HER2 antagonists
    • 6.3.1 HER2 antagonists market estimates and forecast, 2018 - 2030
  • 6.4 VEGFR2 antagonists
    • 6.4.1 VEGFR2 antagonists market estimates and forecast, 2018 - 2030
  • 6.5 Others
    • 6.5.1 Others market estimates and forecast, 2018 - 2030

Chapter 7 Route of Administration Business Analysis

  • 7.1 Stomach Cancer Treatment Market: Route of Administration Movement Analysis
  • 7.2 Oral
    • 7.2.1 Oral market estimates and forecast, 2018 - 2030
  • 7.3 Injectable
    • 7.3.1 Injectable market estimates and forecast, 2018 - 2030

Chapter 8 Distribution Channel Business Analysis

  • 8.1 Stomach Cancer Treatment Market: Distribution Channel Movement Analysis
  • 8.2 Hospital Pharmacies
    • 8.2.1 Hospital Pharmacies market estimates and forecast, 2018 - 2030
  • 8.3 Specialty & Retail Pharmacies
    • 8.3.1 Specialty & Retail Pharmacies market estimates and forecast, 2018 - 2030
  • 8.4 Others
    • 8.4.1 Others market estimates and forecast, 2018 - 2030

Chapter 9 Regional Estimates & Trend Analysis

  • 9.1. Regional Market Snapshot
    • 9.1.1. North America
      • 9.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.1.2. U.S.
      • 9.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.1.3. Canada
      • 9.1.1.3.1. Canada market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.1.2. Europe
      • 9.1.2.1. Europe market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.2.2. U.K.
      • 9.1.2.2.1. U.K. market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.2.3. Germany
      • 9.1.2.3.1. Germany market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.2.4. Spain
      • 9.1.2.4.1. Spain market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.2.5. France
      • 9.1.2.5.1. France market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.2.9. Italy
      • 9.1.2.9.1. Italy market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.1.3. Asia Pacific
      • 9.1.3.1.Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.3.2. China
      • 9.1.3.2.1. China market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.3.3. Japan
      • 9.1.3.3.1. Japan market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.3.4. India
      • 9.1.3.4.1. India market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.3.5. South Korea
      • 9.1.3.5.1. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.3.9. Australia
      • 9.1.3.9.1. Australia market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.1.4. Latin America
    • 9.1.4. Latin America market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.4.1. Brazil
      • 9.1.4.1.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.4.2. Mexico
      • 9.1.4.2.1. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.4.3. Argentina
      • 9.1.4.3.1. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.1.5. Middle East & Africa
      • 9.1.5.1. MEA market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.5.2. South Africa
      • 9.1.5.2.1. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.5.3. Saudi Arabia
      • 9.1.5.3.1. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
      • 9.1.5.4. UAE
      • 9.1.5.4.1. UAE market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 10 Stomach Cancer Market - Competitive Analysis

  • 10.1. Recent developments & impact analysis, by key market participants
  • 10.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
  • 10.3. Public Companies
    • 10.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
    • 10.3.2. Competitive Dashboard Analysis
      • 10.3.2.1. Market Differentiators
  • 10.4. Private Companies
    • 10.4.1. List of key emerging companies' /technology disruptors/innovators
    • 10.4.2. Regional network map
    • 10.4.3. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
  • 10.5. Company Profiles
    • 10.5.1. Eli Lilly and Company
      • 10.5.1.1. Company Overview
      • 10.5.1.2. Financial Performance
      • 10.5.1.3. Product Benchmarking
      • 10.5.1.4. Strategic Initiatives
    • 10.5.2. F. Hoffmann-La Roche Ltd.
      • 10.5.2.1. Company Overview
      • 10.5.2.2. Financial Performance
      • 10.5.2.3. Product Benchmarking
      • 10.5.2.4. Strategic Initiatives
    • 10.5.3. Pfizer Inc.
      • 10.5.3.1. Company Overview
      • 10.5.3.2. Financial Performance
      • 10.5.3.3. Product Benchmarking
      • 10.5.3.4. Strategic Initiatives
    • 10.5.4. Novartis AG
      • 10.5.4.1. Company Overview
      • 10.5.4.2. Financial Performance
      • 10.5.4.3. Product Benchmarking
      • 10.5.4.4. Strategic Initiatives
    • 10.5.5. Merck & Co., Inc.
      • 10.5.5.1. Company Overview
      • 10.5.5.2. Financial Performance
      • 10.5.5.3. Product Benchmarking
      • 10.5.5.4. Strategic Initiatives
    • 10.5.6. Samsung Bioepis
      • 10.5.6.1. Company Overview
      • 10.5.6.2. Financial Performance
      • 10.5.6.3. Product Benchmarking
      • 10.5.6.4. Strategic Initiatives
    • 10.5.10. Biocon
      • 10.5.10.1. Company Overview
      • 10.5.10.2. Financial Performance
      • 10.5.10.3. Product Benchmarking
      • 10.5.10.4. Strategic Initiatives
    • 10.5.8. Mylan N.V.
      • 10.5.8.1. Company Overview
      • 10.5.8.2. Financial Performance
      • 10.5.8.3. Product Benchmarking
      • 10.5.8.4. Strategic Initiatives
    • 10.5.9. Teva Pharmaceutical Industries Ltd.
      • 10.5.9.1. Company Overview
      • 10.5.9.2. Financial Performance
      • 10.5.9.3. Product Benchmarking
      • 10.5.9.4. Strategic Initiatives
    • 10.5.10. Celltrion Healthcare Co., Ltd.
      • 10.5.10.1. Company Overview
      • 10.5.10.2. Financial Performance
      • 10.5.10.3. Product Benchmarking
      • 10.5.10.4. Strategic Initiatives

List of Tables

  • TABLE 1 List of Secondary Sources
  • TABLE 2 List of Abbreviations
  • TABLE 3 Global Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (Patient Share in %, USD Million)
  • TABLE 4 Global Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (Patient Share in %, USD Million)
  • TABLE 5 Global Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 6 Global Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 7 Global Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 8 Global Stomach Cancer Treatment market, by Region, 2018 - 2030 (USD Million)
  • TABLE 9 North America Stomach Cancer Treatment market, by Country, 2018 - 2030 (USD Million)
  • TABLE 10 North America Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 11 North America Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 12 North America Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 13 North America Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 14 North America Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 15 U.S. Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 16 U.S. Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 17 U.S. Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 18 U.S. Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 19 U.S. Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 20 Canada Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 21 Canada Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 22 Canada Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 23 Canada Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 24 Canada Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 25 Europe Stomach Cancer Treatment market, by Country, 2018 - 2030 (USD Million)
  • TABLE 26 Europe Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 27 Europe Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 28 Europe Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 29 Europe Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 30 Europe Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 31 Germany Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 32 Germany Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 33 Germany Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 34 Germany Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 35 Germany Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 36 U.K. Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 37 U.K. Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 38 U.K. Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 39 U.K. Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 40 U.K. Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 41 France Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 42 France Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 43 France Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 44 France Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 45 France Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 46 Italy Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 47 Italy Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 48 Italy Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 49 Italy Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 50 Italy Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 51 Spain Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 52 Spain Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 53 Spain Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 54 Spain Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 55 Spain Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 56 Asia Pacific Stomach Cancer Treatment market, by Country, 2018 - 2030 (USD Million)
  • TABLE 57 Asia Pacific Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 58 Asia Pacific Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 59 Asia Pacific Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 60 Asia Pacific Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 61 Asia Pacific Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 62 China Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 63 China Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 64 China Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 65 China Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 66 China Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 67 Japan Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 68 Japan Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 69 Japan Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 70 Japan Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 71 Japan Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 72 India Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 73 India Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 74 India Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 75 India Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 76 India Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 77 South Korea Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 78 South Korea Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 79 South Korea Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 80 South Korea Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 81 South Korea Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 82 Australia Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 83 Australia Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 84 Australia Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 85 Australia Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 86 Australia Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 87 Latin America Stomach Cancer Treatment market, by Country, 2018 - 2030 (USD Million)
  • TABLE 88 Latin America Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 89 Latin America Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 90 Latin America Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 91 Latin America Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 92 Latin America Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 93 Brazil Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 94 Brazil Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 95 Brazil Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 96 Brazil Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 97 Brazil Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 98 Mexico Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 99 Mexico Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 100 Mexico Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 101 Mexico Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 102 Mexico Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 103 Argentina Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 104 Argentina Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 105 Argentina Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 106 Argentina Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 107 Argentina Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 108 Middle East & Africa Stomach Cancer Treatment market, by Country, 2018 - 2030 (USD Million)
  • TABLE 109 Middle East & Africa Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 110 Middle East & Africa Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 111 Middle East & Africa Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 112 Middle East & Africa Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 113 Middle East & Africa Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 114 South Africa Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 115 South Africa Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 116 South Africa Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 117 South Africa Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 118 South Africa Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 119 Saudi Arabia Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 120 Saudi Arabia Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 121 Saudi Arabia Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 122 Saudi Arabia Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 123 Saudi Arabia Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 124 UAE Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 125 UAE Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
  • TABLE 126 UAE Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 127 UAE Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
  • TABLE 128 UAE Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary Research Pattern
  • FIG. 4 Market Research Approaches
  • FIG. 5 Epidemiology - based market sizing & Forecasting
  • FIG. 6 Market Formulation & Validation
  • FIG. 7 Stomach Cancer Treatment Market, Market Segmentation
  • FIG. 8 Market Snapshot, 2021
  • FIG. 9 Market Trends & Outlook
  • FIG. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • FIG. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • FIG. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • FIG. 13 Porter's Five Forces Analysis
  • FIG. 14 Market Penetration Vs Growth Prospect Mapping, 2021
  • FIG. 15 Global Stomach Cancer Treatment Market:Treatment Type Movement Analysis
  • FIG. 16 Global Stomach Cancer Treatment Market, for Chemotherapy, 2018 - 2030 (Patient Share in %, USD Million)
  • FIG. 17 Global Stomach Cancer Treatment Market, for Immunotherapy, 2018 - 2030 (Patient Share in %, USD Million)
  • FIG. 18 Global Stomach Cancer Treatment Market, for Targeted drugs, 2018 - 2030 (Patient Share in %, USD Million)
  • FIG. 19 Global Stomach Cancer Treatment Market: Disease Indication Movement Analysis
  • FIG. 20 Global Stomach Cancer Treatment Market, for Gastric Cancer/Gastroesophageal Junction Cancer, 2018 - 2030 (USD Million)
  • FIG. 21 Global Stomach Cancer Treatment Market, for Gastrointestinal Stromal Tumors, 2018 - 2030 (USD Million)
  • FIG. 22 Global Stomach Cancer Treatment Market: Route of Administration Movement Analysis
  • FIG. 23 Global Stomach Cancer Treatment Market, for Oral, 2018 - 2030 (USD Million)
  • FIG. 24 Global Stomach Cancer Treatment Market, for Injectable, 2018 - 2030 (USD Million)
  • FIG. 25 Global Stomach Cancer Treatment Market: Drug Class, Movement Analysis
  • FIG. 26 Global Stomach Cancer Treatment Market, for PD - 1/ PD - L1 inibitors, 2018 - 2030 (Patient Share in %, USD Million)
  • FIG. 27 Global Stomach Cancer Treatment Market, for HER2 Antagonists, 2018 - 2030 (Patient Share in %, USD Million)
  • FIG. 28 Global Stomach Cancer Treatment Market, for VEGFR Antagonists, 2018 - 2030 (Patient Share in %, USD Million)
  • FIG. 29 Global Stomach Cancer Treatment Market, for Others, 2018 - 2030 (Patient Share in %, USD Million)
  • FIG. 30 Global Stomach Cancer Treatment Market: Distribution Channel, Movement Analysis
  • FIG. 31 Global Stomach Cancer Treatment Market, for Hospital Pharmacies, 2018 - 2030 (USD Million)
  • FIG. 32 Global Stomach Cancer Treatment Market, for Specialty & Retail Pharmacies, 2018 - 2030 (USD Million)
  • FIG. 33 Global Stomach Cancer Treatment Market, for Others, 2018 - 2030 (USD Million)
  • FIG. 34 Regional Marketplace: Key Takeaways
  • FIG. 35 Regional Outlook, 2021 & 2030
  • FIG. 36 Global Stomach Cancer Treatment Market: Regional Movement Analysis
  • FIG. 37 North AmericaStomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 38 U.S. Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 39 Canada Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 40 Europe Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 41 Germany Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 42 U.K. Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 43 France Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 44 Italy Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 45 Spain Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 46 Asia Pacific Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 47 Japan Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 48 China Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 49 India Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 50 Australia Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 51 South Korea Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 52 Latin AmericaStomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 53 Brazil Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 54 Mexico Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 55 Argentina Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 56 Middle East and Africa Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 57 South Africa Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 58 Saudi Arabia Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
  • FIG. 59 UAE Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)